JOP20200128A1 - صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها - Google Patents
صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجهاInfo
- Publication number
- JOP20200128A1 JOP20200128A1 JOP/2020/0128A JOP20200128A JOP20200128A1 JO P20200128 A1 JOP20200128 A1 JO P20200128A1 JO P20200128 A JOP20200128 A JO P20200128A JO P20200128 A1 JOP20200128 A1 JO P20200128A1
- Authority
- JO
- Jordan
- Prior art keywords
- pyrimidinylamino
- polymorphs
- production
- methods
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بصورة متعددة الأشكال متبلرة وصور غير متبلرة من 2-ميثيل-2-(3-ميثيل-4-(4-(ميثيل أمينو)-5-(تراي فلورو ميثيل)بيريميدين-2-يل أمينو)-1H-بيرازول-1-يل)بروبان نيتريل أو ذوابات، أشكال صنوية، وأملاح أو بلورات مشتركة مقبولة صيدليًا منها، وعمليات لتحضيرها. الشكل 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762589276P | 2017-11-21 | 2017-11-21 | |
PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200128A1 true JOP20200128A1 (ar) | 2020-05-21 |
Family
ID=66631734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0128A JOP20200128A1 (ar) | 2017-11-21 | 2018-11-20 | صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها |
Country Status (22)
Country | Link |
---|---|
US (3) | US10370361B2 (ar) |
EP (1) | EP3717473B1 (ar) |
JP (1) | JP7303821B2 (ar) |
KR (1) | KR20200089713A (ar) |
CN (1) | CN111819174A (ar) |
AR (1) | AR113893A1 (ar) |
AU (1) | AU2018372180B2 (ar) |
BR (1) | BR112020010215A2 (ar) |
CA (1) | CA3083022A1 (ar) |
CL (1) | CL2020001346A1 (ar) |
CO (1) | CO2020006206A2 (ar) |
CR (1) | CR20200216A (ar) |
EA (1) | EA202091279A1 (ar) |
IL (1) | IL274824A (ar) |
JO (1) | JOP20200128A1 (ar) |
MA (1) | MA51222A (ar) |
MX (1) | MX2020005332A (ar) |
PE (1) | PE20210157A1 (ar) |
SG (1) | SG11202004733WA (ar) |
TW (1) | TWI823878B (ar) |
UA (1) | UA126414C2 (ar) |
WO (1) | WO2019104086A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3717473B1 (en) | 2017-11-21 | 2024-01-10 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
WO2019126383A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
SI2576541T1 (sl) | 2010-06-04 | 2016-07-29 | F. Hoffmann-La Roche Ag | Aminopirimidinski derivati kot modulatorji lrrk2 |
GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
NO2638031T3 (ar) | 2010-11-10 | 2018-03-10 | ||
ES2638595T3 (es) | 2011-11-29 | 2017-10-23 | Genentech, Inc. | Derivados de aminopirimidina como moduladores de LRRK2 |
US8796296B2 (en) | 2011-11-29 | 2014-08-05 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
JP6180426B2 (ja) | 2011-11-29 | 2017-08-16 | ジェネンテック, インコーポレイテッド | パーキンソン病の処置のためのキナーゼlrrk2モジュレーターとしての2−(フェニル又はピリド−3−イル)アミノピリミジン誘導体 |
AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
KR102091895B1 (ko) | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
KR102091894B1 (ko) * | 2012-05-03 | 2020-03-20 | 제넨테크, 인크. | Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
MD3472153T2 (ro) * | 2016-06-16 | 2022-03-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1H-pirazoli în calitate de inhibitori L RRK2 pentru utilizare în tratamentul tulburărilor neurodegenerative |
EP3717473B1 (en) * | 2017-11-21 | 2024-01-10 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
-
2018
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG11202004733WA (en) | 2020-06-29 |
US20190194170A1 (en) | 2019-06-27 |
EP3717473A1 (en) | 2020-10-07 |
BR112020010215A2 (pt) | 2020-11-03 |
US11427571B2 (en) | 2022-08-30 |
US20210087176A1 (en) | 2021-03-25 |
TW201925190A (zh) | 2019-07-01 |
MA51222A (fr) | 2020-10-07 |
KR20200089713A (ko) | 2020-07-27 |
WO2019104086A1 (en) | 2019-05-31 |
JP2021504450A (ja) | 2021-02-15 |
MX2020005332A (es) | 2021-01-08 |
TWI823878B (zh) | 2023-12-01 |
PE20210157A1 (es) | 2021-01-26 |
UA126414C2 (uk) | 2022-09-28 |
AR113893A1 (es) | 2020-06-24 |
US10370361B2 (en) | 2019-08-06 |
CR20200216A (es) | 2021-03-19 |
EP3717473B1 (en) | 2024-01-10 |
IL274824A (en) | 2020-07-30 |
EA202091279A1 (ru) | 2020-08-19 |
CL2020001346A1 (es) | 2020-11-20 |
CN111819174A (zh) | 2020-10-23 |
EP3717473A4 (en) | 2021-07-07 |
JP7303821B2 (ja) | 2023-07-05 |
US20190315723A1 (en) | 2019-10-17 |
AU2018372180B2 (en) | 2023-08-17 |
AU2018372180A1 (en) | 2020-06-18 |
CO2020006206A2 (es) | 2020-08-10 |
CA3083022A1 (en) | 2019-05-31 |
US10851088B2 (en) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018550120A1 (en) | Steroid derivative fxr agonist | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
WO2015132799A3 (en) | Heterocyclic compounds | |
MY199931A (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
MX2016013564A (es) | Inhibidores heterociclicos de cinasas. | |
IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
MX2021009764A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
MD3882250T2 (ro) | Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK | |
JOP20200128A1 (ar) | صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
MX2021008002A (es) | Sales nuevas y forma polimorfica del acido bempedoico. | |
MX2019015886A (es) | Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-0xoisoindolin-5-il)metil)-2,2-difluoroacetamid a. | |
EP4275707A3 (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
PH12016501903A1 (en) | Novel fused imidazobenzothiazole compounds | |
WO2016023028A3 (en) | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | |
WO2015111085A8 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
PH12017501532A1 (en) | Crystalline forms of a pyrrolopyridine compound | |
PH12017500323B1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
HK1221225A1 (zh) | -二氨基吡唑激酶抑制劑的藥學上可接受的鹽 | |
WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin | |
PH12020500385A1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
MX2021014705A (es) | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. |